PNEOO
LIVE

Serial Number

79407300

Owner

PNEOO B.V.

Attorney

Cheryl L. Burbach

Filing Date

Aug 8, 2024

Add to watchlist:

No watchlists yet
View on USPTO

PNEOO Trademark

Serial Number: 79407300 • Registration: 8226523

PNEOO is a trademark filed by PNEOO B.V. on August 8, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

PNEOO B.V. (3 trademarks)

Commerdaelseweg 8

Entity Type: 26

Trademark Details

Filing Date

August 8, 2024

Registration Date

April 28, 2026

Published for Opposition

March 10, 2026

Goods & Services

Medical research services for the treatment of various medical disorders, cancer, pulmonary diseases, respiratory diseases, and infectious diseases; Scientific laboratory services; scientific research for medical purposes in the area of diseases; scientific research in the field of genetics and genetic engineering; genetic research for scientific research purposes; genetic mapping for scientific purposes; DNA screening for scientific research purposes; DNA analysis services for scientific research purposes; providing scientific research information in the field of medical disorders and their treatment; biotechnological research relating to enzymatic synthesis; toxicity testing for scientific research purposes; toxicity analysis for scientific research purposes; software as a service (SaaS) featuring artificial intelligence software for use in database management relating to the medical field; software as a service (SaaS) featuring software for use in data base management relating to the medical field; all of the aforementioned services solely related to respiratory and pulmonary diseases, including lung cancer

Medical, biological, and pharmaceutical preparations for the treatment of pulmonary diseases; veterinary preparations for pets, cattle, livestock for preventing and treating infectious diseases, medical disorders, and diseases, namely, lung cancer; medical, biological, and pharmaceutical preparations for preventing and treating infectious diseases, medical disorders, and diseases, namely, lung cancer; medical, biological, and pharmaceutical preparations for preventing and treating viral, bacterial, and yeast infections; veterinary preparations for pets, cattle, livestock for preventing and treating viral, bacterial, and yeast infections; medical, biological, and pharmaceutical preparations for preventing and treating cancer, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; veterinary preparations for pets, cattle, livestock for preventing and treating cancer, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; vaccines; regulatory proteins for medical use, namely, protein arrays for medical diagnosis purposes, the foregoing solely related to respiratory and pulmonary diseases, including lung cancer; pharmaceutical compounds being a component in pharmaceutical preparations for treating respiratory diseases; pharmaceutical preparations for the prevention of diseases of the respiratory system; diagnostic preparations for medical purposes, the foregoing solely related to respiratory and pulmonary diseases, including lung cancer; chemical diagnostic reagents for medical use, the foregoing solely related to respiratory and pulmonary diseases, including lung cancer

Biological preparations for use in cell cultures, other than for medical or veterinary purposes, for boosting cells in the immune system for improved therapies; biological preparations for use in cell cultures, in the nature of genetically modified cells and vectors for scientific and research purposes; biological and chemical reagents in the nature of complexes of molecules for scientific research and for clinical and industrial use; proteins for use in scientific research; regulatory proteins in raw material for scientific research; the aforementioned goods solely related to respiratory and pulmonary diseases, including lung cancer

Provision of information, advice and consultancy services in the fields of cell therapy, gene editing, protein replacement, and antibodies, the aforementioned services solely related to respiratory and pulmonary diseases, including lung cancer

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 28, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 28, 2026 R.PR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 13, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 13, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 13, 2026 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 13, 2026 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Apr 13, 2026 COAR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Apr 9, 2026 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 23, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 23, 2026 OPNR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 10, 2026 NPUB
PUBLISHED FOR OPPOSITION
Mar 10, 2026 PUBO
NOTIFICATION PROCESSED BY IB
Mar 5, 2026 GPNX
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 4, 2026 NONP
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 18, 2026 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Feb 17, 2026 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 10, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 31, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 31, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 31, 2025 TROA
NEW REPRESENTATIVE AT IB RECEIVED
Nov 14, 2025 NREP
REFUSAL PROCESSED BY IB
Nov 7, 2025 RFNT
NON-FINAL ACTION WRITTEN
Oct 9, 2025 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 8, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 8, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 8, 2025 TROA
REFUSAL PROCESSED BY IB
Apr 12, 2025 RFNT
NEW REPRESENTATIVE AT IB RECEIVED
Mar 28, 2025 NREP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 27, 2025 RFCS
REFUSAL PROCESSED BY MPU
Mar 27, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 21, 2025 RFCR
NON-FINAL ACTION WRITTEN
Feb 20, 2025 CNRT
ASSIGNED TO EXAMINER
Feb 13, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 24, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 24, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 24, 2024 REPR